Clinical Trial Update: Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial update on enasidenib with azacitidine for recurrent or refractory acute myeloid leukemia with IDH2 mutation, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Mixed Phenotype Acute Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Enasidenib (enasidenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Status: RECRUITING